Biodexa Pharmaceuticals
BDRX
6 hedge funds and large institutions have $228K invested in Biodexa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
266% more capital inflows, than outflows
Capital inflows: $111K | Capital outflows: $30.4K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
7.61% more ownership
Funds ownership: 36.39% → 44% (+7.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less funds holding
Funds holding: 8 → 6 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$94.1K |
| 2 |
GAMMA Investing
Foster City,
California
|
+$16.9K |
| 3 |
SBI Securities
Tokyo,
Japan
|
+$56 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$24K |
| 2 |
Armistice Capital
New York
|
-$3.49K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.81K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$56 |
BDRX Hedge Fund Activity: Q1 2026 in Review
6 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2026, worth a combined $228K — down 67% from $693K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BDRX and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $94.1K. The largest seller was HRT Financial, exiting entirely with an estimated $24K sold.
- 6 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2026, down from 8 in Q4 2025.
- Funds reported $228K of Biodexa Pharmaceuticals stock for Q1 2026, down 67% quarter-over-quarter.
- 0 funds opened new Biodexa Pharmaceuticals positions in Q1 2026 and 2 closed out, a net change of -2 holders.
- The largest Biodexa Pharmaceuticals buyer in Q1 2026 was Sabby Management, an estimated $94.1K added.
- The largest Biodexa Pharmaceuticals seller in Q1 2026 was HRT Financial, an estimated $24K sold.
Based on aggregated 13F filings for Q1 2026.